FLOW studied semaglutide in adults with type 2 diabetes and chronic kidney disease. Its findings concern a defined group, treatment and combined outcome. They do not establish that every GLP-1 prescription prevents kidney problems in every person seeking weight loss.
Who took part in FLOW?
The original 2024 trial report describes 3,533 participants assigned to weekly semaglutide or placebo, with a median follow-up of 3.4 years. Participants had type 2 diabetes and met specified kidney-function and urine-albumin criteria. This was not a trial in the general population without those diagnoses.
The study was funded by Novo Nordisk. Early cessation followed a prespecified interim analysis. Read that stopping decision alongside the reported follow-up and the outcome the researchers actually counted.
What the 24% figure means
The primary outcome combined kidney failure, a large decline in kidney function and death from kidney-related or cardiovascular causes. There were 331 first events with semaglutide and 410 with placebo. The hazard ratio was 0.76, reported as a 24% lower relative risk of this combined outcome.
It was not a 24-percentage-point reduction, a 24% improvement in every patient’s kidney function or a result about dialysis alone. The combined outcome includes cardiovascular death, which a shortened “kidney protection” headline can leave out.
Keep the approved use attached to the product
The current Ozempic label includes reducing the risk of sustained kidney-function decline, end-stage kidney disease and cardiovascular death in adults with both type 2 diabetes and chronic kidney disease. That indication does not automatically transfer to another product, a compounded formulation or a person who has obesity without those diagnoses.
Kidney benefit still requires attention to illness
Ozempic’s label also warns about acute kidney injury associated with fluid loss and calls for monitoring when adverse reactions could cause dehydration. For the practical distinction, read why kidney benefits and dehydration warnings can both be true.
Follow individualized fluid advice. NIDDK explains that some people with chronic kidney disease need to limit liquids. A generic instruction to drink more cannot account for an existing restriction or a new illness.
Questions for a treatment review
- Does my diagnosis match the evidence being discussed?
- Which exact medicine and treatment goal are being considered?
- How does the prescription fit with my existing kidney-care plan?
- Who will review test results or new symptoms between appointments?
Use the original-source guide to check an incomplete health claim. If you are comparing online weight-management services, our CoreAge Rx review addresses the service rather than claiming kidney outcomes from FLOW for its patients. Confirm the service’s scope with a clinician and involve the team already managing any kidney disease.
Sources checked September 9, 2026. This is a commercial publisher’s research summary, not a government statement or an individual treatment recommendation.